Cidara Therapeutics, Inc. (CDTX) has 20 bekannte Insider- und institutionelle Anteilseigner verzeichnet. Der größte Anteilseigner ist Mundipharma AG mit 4,781,408 Aktien. Weitere bedeutende Anteilseigner sind BIOTECH TARGET N V und Stein Jeffrey.
In den letzten 12 Monaten haben Insider 13 Transaktionen in CDTX Aktien getätigt — 12 Käufe (im Wert von $2.38M) und 0 Verkäufe (im Wert von RSU Award). Insider-Käufe haben die Verkäufe übertroffen, was auf Vertrauen in die Unternehmensaussichten hindeuten kann.
CDTX Insider-Beteiligungen
Größter Aktionär
Mundipharma AG
4,781,408 Aktien
Käufe (12 Monate)
12
$2.38M Wert
Verkäufe (12 Monate)
0
$0.00 Wert
12-Monats-Transaktionsaktivität
Top-Insider-Aktionäre
| # |
Name |
Funktion |
Gehaltene Aktien |
Zuletzt gemeldet |
Relative Größe |
| 1 |
Mundipharma Ag |
10 Percent Owner |
4,781,408 |
2019-09-13 |
|
| 2 |
Biotech Target N V |
10 Percent Owner |
2,295,272 |
2017-11-16 |
|
| 3 |
Stein Jeffrey |
President & CEO |
275,000 |
2025-04-02 |
|
| 4 |
Daruwala Paul |
Chief Operating Officer |
221,099 |
2022-09-13 |
|
| 5 |
Sandison Taylor |
Chief Medical Officer |
166,836 |
2024-10-02 |
|
| 6 |
Shah Preetam |
Chief Financial Officer |
130,087 |
2024-10-02 |
|
| 7 |
Levine James E. |
Chief Financial Officer |
130,000 |
2021-03-19 |
|
| 8 |
Judice Kevin |
Director |
94,488 |
2015-04-14 |
|
| 9 |
Thye Dirk |
Chief Medical Officer |
80,000 |
2016-03-18 |
|
| 10 |
Onaitis Matthew |
Gnrl Counsel, CFO & Secretary |
72,000 |
2018-04-02 |
|
| 11 |
Forrest Kevin |
Chief Scientific Officer |
60,000 |
2017-04-04 |
|
| 12 |
Karbe Frank |
Chief Financial Officer |
57,500 |
2025-02-26 |
|
| 13 |
Abdollahian Neil |
Chief Business Officer |
55,440 |
2021-04-05 |
|
| 14 |
Bartizal Ken |
Chief Development Officer |
50,000 |
2017-04-04 |
|
| 15 |
Franson Timothy R |
Director |
42,500 |
2023-06-23 |
|
| 16 |
Gollaher David L |
Director |
42,500 |
2023-06-23 |
|
| 17 |
Ward Shane |
COO & CLO |
39,674 |
2025-04-02 |
|
| 18 |
Davarpanah Nicole Negar |
Chief Medical Officer |
20,000 |
2025-05-12 |
|
| 19 |
Johnson Brady |
Vice President, Finance |
20,000 |
2022-04-04 |
|
| 20 |
Tari Leslie |
Chief Scientific Officer |
16,215 |
2025-03-13 |
|
Aktuelle Transaktionen (letzte 12 Monate)
| Datum |
Name |
Funktion |
Typ |
Aktien |
Kurs |
Wert |
| 2025-06-18 |
Merson James |
Director |
RSU-Zuteilung |
11,100 |
$21.31 |
$236.54K |
| 2025-06-18 |
Canale-theakston Carin |
Director |
RSU-Zuteilung |
11,100 |
$21.31 |
$236.54K |
| 2025-06-18 |
Spencer Ryan |
Director |
RSU-Zuteilung |
11,100 |
$21.31 |
$236.54K |
| 2025-06-18 |
Resnick Joshua |
Director |
RSU-Zuteilung |
5,079 |
$21.31 |
$108.23K |
| 2025-06-18 |
Bassler Bonnie L |
Director |
RSU-Zuteilung |
11,100 |
$21.31 |
$236.54K |
| 2025-06-18 |
Mineo Chrysa |
Director |
RSU-Zuteilung |
11,100 |
$21.31 |
$236.54K |
| 2025-06-18 |
Schroeder Theodore R |
Director |
RSU-Zuteilung |
11,100 |
$21.31 |
$236.54K |
| 2025-06-18 |
Ra Capital Management, L.p. |
Director |
RSU-Zuteilung |
5,079 |
$21.31 |
$108.23K |
| 2025-06-18 |
Burgess Daniel D |
Director |
RSU-Zuteilung |
11,100 |
$21.31 |
$236.54K |
| 2025-06-03 |
Mineo Chrysa |
Director |
Informierter Kauf |
1,050 |
$23.44 |
$24.61K |
| 2025-06-02 |
Mineo Chrysa |
Director |
Informierter Kauf |
2,270 |
$21.71 |
$49.28K |
| 2025-05-01 |
Davarpanah Nicole Negar |
Chief Medical Officer |
RSU-Zuteilung |
20,000 |
$21.75 |
$435K |
| 2025-05-01 |
Davarpanah Nicole Negar |
Chief Medical Officer |
Unbekannt |
30,000 |
$21.54 |
$646.2K |
